Zoetis Inc. Class A ($ZTS) Stock Forecast: Down 5.2% Today

What is Zoetis Inc. Class A?

Zoetis Inc. (ZTS) is a leading global animal health company specializing in medicines, vaccines, and diagnostic products for livestock and companion animals.

Why is Zoetis Inc. Class A going down?

ZTS stock is down 5.2% on Mar 6, 2026 15:07

• Zoetis Inc. (ZTS) witnessed a bearish market movement.
• The bearish trend could be linked to mixed results in the branded pharmaceutical sector, particularly highlighted in the Q4 earnings.
• While some companies like Bristol-Myers Squibb and Eli Lilly exceeded revenue expectations, the sector as a whole fell short of estimates, affecting investor sentiment.
• Moreover, a market report forecasting growth in the injected veterinary pain management drugs market may have raised concerns about potential competition for Zoetis Inc., influencing the negative market response.
• In conclusion, the underperformance of the sector combined with potential market challenges may have contributed to the bearish movement in Zoetis Inc. (ZTS) stock.

ZTS Price Chart

ZTS Technical Analysis

ZTS News

Steven Klinsky Buys 250,495 Shares of New Mountain Finance (NASDAQ:NMFC) Stock

Director Steven Klinsky has purchased 250,495 shares of New Mountain Finance (NASDAQ:NMFC) for approximately $1.99 million, increasing his stake to 4,754,338 shares. Despite a quarterly dividend implying a 15.8% yield, the company's dividend payout ratio is an unsustainably high 853.33%. Analysts have a "Reduce" rating on NMFC with an average price target of $9.25, and institutional investors have also adjusted their positions in the company.

https://www.marketbeat.com/instant-alerts/steven-klinsky-buys-250495-shares-of-new-mountain-finance-nasdaqnmfc-stock-2026-03-05/

Deutsche Raises its Price Target on Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) to EUR 21.24 and Maintains a Buy Rating

Deutsche Bank has increased its price target for Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) to EUR 21.24 from EUR 19.75, reaffirming a Buy rating due to improved net interest income and higher return on tangible equity forecasts. This follows recent adjustments by other banks, with RBC Capital also raising its price target while changing its rating to Sector Perform, and Morgan Stanley slightly lowering its target but maintaining an Equal Weight rating. The article also touches on BBVA's diverse banking and financial services across multiple regions and suggests exploring AI stocks for higher upside potential.

https://finviz.com/news/330852/deutsche-raises-its-price-target-on-banco-bilbao-vizcaya-argentaria-sa-bbva-to-eur-2124-and-maintains-a-buy-rating

Injected Veterinary Pain Management Drugs Market Set to Witness Rapid Growth Through 2033 | Zoetis Inc., Elanco Animal Health Incorporated

Coherent Market Insights has released a detailed report on the "Injected Veterinary Pain Management Drugs Market," forecasting rapid growth through 2033. The report provides an in-depth analysis of market trends, challenges, opportunities, competitive dynamics, and regional performance, featuring key players like Zoetis Inc. and Elanco Animal Health Incorporated. It aims to serve as a crucial decision-support tool for industry stakeholders, covering critical success factors, risk assessment, and financial analysis.

https://www.openpr.com/news/4414093/injected-veterinary-pain-management-drugs-market-set-to-witness

Integrated Quantitative Investments LLC Takes $1.34 Million Position in United Natural Foods, Inc. $UNFI

Integrated Quantitative Investments LLC has acquired a new position in United Natural Foods, Inc. (UNFI), purchasing 35,685 shares worth approximately $1.34 million in the third quarter, representing about 0.06% of the company. Institutional investors collectively own 87.63% of UNFI, while insiders hold 2.40%, with recent insider transactions including a director buying shares and another insider selling shares. Analysts currently have an average "Hold" rating for UNFI with a mean price target of $38.78.

https://www.marketbeat.com/instant-alerts/filing-integrated-quantitative-investments-llc-takes-134-million-position-in-united-natural-foods-inc-unfi-2026-03-05/

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

This article reviews the Q4 earnings performance of several branded pharmaceutical companies, highlighting Bristol-Myers Squibb (BMY), Eli Lilly (LLY), Corcept (CORT), Supernus Pharmaceuticals (SUPN), and Zoetis (ZTS). While the sector as a whole had mixed results, with revenues generally missing estimates, Bristol-Myers Squibb and Eli Lilly posted strong revenue beats. Corcept, however, significantly missed analyst expectations for revenue and EPS.

https://www.tradingview.com/news/stockstory:11119a321094b:0-q4-earnings-outperformers-bristol-myers-squibb-nyse-bmy-and-the-rest-of-the-branded-pharmaceuticals-stocks/

Trending Today

Ethereum ($ETH) Crypto Forecast: Down 5.5% Today

Dogecoin ($DOGE) Crypto Forecast: Down 5.3% Today

Zoetis Inc. Class A Price History

15.08.2025 - ZTS Stock was down 1.8%

• Zoetis (ZTS) stock experienced a bearish movement today, closing at $149.79 with a -1.29% change compared to its last close.
• A recent comparison between SDZNY and ZTS may have raised concerns among investors about the valuation and attractiveness of Zoetis stock.
• The overall market gains might have shifted investor focus towards other sectors or stocks, leading to a sell-off in Zoetis shares.
• The negative market sentiment towards Zoetis could also be influenced by broader economic factors or industry-specific news impacting the Medical Drugs sector.

18.05.2025 - ZTS Stock was down 5.2%

• The bearish movement in Zoetis (ZTS) today may be attributed to the following factors:
• Despite outperforming market returns recently, the stock could be facing profit-taking by investors following a period of gains.
• Shifting market sentiment towards the animal health sector, possibly influenced by concerns over regulatory changes or competitive pressures.
• External factors such as overall market volatility or economic indicators potentially impacting the stock's decline today.
• Investor response to undisclosed news or events concerning Zoetis (ZTS), contributing to a downward trend in the stock price.

12.01.2026 - ZTS Stock was down 6.7%

• Zoetis Inc. (ZTS) achieved strong Q4 revenue of $2.39 billion, exceeding expectations, and offered optimistic 2026 guidance.
• Despite the positive financial results, the downward trend in ZTS stock may be linked to investors taking profits following a period of growth.
• The anticipated growth of the animal vaccine market suggests a favorable future for Zoetis, although market sentiment and broader economic factors could have impacted the stock's decline.
• Investor apprehension may stem from market uncertainties and potential competition from other industry players like Merck and Boehringer Ingelheim within the animal vaccine sector.

12.01.2026 - ZTS Stock was down 1.0%

• Zoetis Inc. (ZTS) posted impressive Q4 revenue of $2.39 billion, surpassing expectations. However, despite this positive performance, the stock witnessed a bearish trend.
• The State of Michigan Retirement System's investment in Elanco Animal Health (ELAN) and favorable views on Elanco by analysts could have diverted investor focus from Zoetis, impacting its stock trajectory.
• Anticipated growth in the animal vaccine market overall and heightened competition from industry players such as Merck and Boehringer Ingelheim may have also played a role in the bearish movement of Zoetis stock.
• The lowered earnings forecast for USANA Health Sciences (USNA) and advised caution by analysts on its stock could have prompted a shift in investor sentiment towards other companies within the animal health sector, including Zoetis.

13.01.2026 - ZTS Stock was up 6.6%

• Zoetis Inc. (ZTS) experienced a strong bullish movement today following its impressive Q4 earnings and optimistic 2026 guidance.
• The company reported Q4 revenue and adjusted EPS that exceeded estimates, showcasing strong financial performance.
• The positive market reaction can be attributed to Zoetis' solid financial results and optimistic outlook for future revenue and earnings growth, indicating investor confidence in the company's strategic direction and market positioning.
• This bullish momentum for Zoetis might have been further fueled by the overall positive sentiment in the animal health industry, as evidenced by institutional investments in related companies like Elanco Animal Health.

21.10.2025 - ZTS Stock was up 3.3%

• Recent fluctuations in the stock price over the last month and year have been overshadowed by today's positive movement of 0.38% to $117.53, hinting at a possible change in investor sentiment.
• The upward price trend could be linked to investors acknowledging Zoetis Inc.'s enduring value and growth opportunities within the animal health sector.
• Shareholders are displaying optimism regarding the company's future, fueling heightened buying activity and lifting the stock price.
• The surge in price relative to earnings signifies a reassessment of Zoetis Inc.'s worth by investors, positioning it as a potentially undervalued asset in the market.

21.10.2025 - ZTS Stock was up 5.2%

• Zoetis Inc. (ZTS) saw a significant bullish movement today, despite recent declines in stock price over the past month and year.
• Analysts are raising concerns about potential challenges in Zoetis' osteoarthritis pain franchise in a competitive market.
• The surge in Zoetis' stock price today may be linked to market optimism or positive developments within the company.
• Investors are keeping a close eye on Zoetis Inc.'s price over earnings ratio to assess if the stock is undervalued, potentially impacting today's bullish movement.

06.02.2026 - ZTS Stock was down 5.2%

• Zoetis Inc. (ZTS) witnessed a bearish market movement.
• The bearish trend could be linked to mixed results in the branded pharmaceutical sector, particularly highlighted in the Q4 earnings.
• While some companies like Bristol-Myers Squibb and Eli Lilly exceeded revenue expectations, the sector as a whole fell short of estimates, affecting investor sentiment.
• Moreover, a market report forecasting growth in the injected veterinary pain management drugs market may have raised concerns about potential competition for Zoetis Inc., influencing the negative market response.
• In conclusion, the underperformance of the sector combined with potential market challenges may have contributed to the bearish movement in Zoetis Inc. (ZTS) stock.

04.10.2025 - ZTS Stock was down 12.0%

• Despite surpassing Q3 earnings estimates, Zoetis (ZTS) experienced a strong bearish movement in the market.
• The market may have reacted negatively due to the slight revenue miss and uncertainties about future growth prospects.
• Investors might have been expecting even stronger performance given the rising demand for companion animal products like Simparica Trio and Apoquel.
• The bearish movement could also be influenced by profit-taking behavior following a period of sustained growth in the stock price.

04.10.2025 - ZTS Stock was down 13.3%

• Despite beating third-quarter earnings estimates, Zoetis (ZTS) experienced a bearish market movement due to rising competitive pressures in the animal health industry.
• The company's revenue growth expectations driven by products like Simparica Trio and Apoquel were overshadowed by concerns about increasing competition impacting future profitability.
• Investors may have reacted negatively to the uncertainty surrounding Zoetis' ability to maintain its market position amidst growing competitive pressures, leading to the bearish movement in the stock price.

04.10.2025 - ZTS Stock was down 12.4%

• The bearish movement in ZTS stock today could be attributed to profit-taking by investors after a period of strong growth.
• Despite expectations of another earnings beat and anticipated revenue growth driven by popular products like Simparica Trio and Apoquel, the market may have had higher expectations than what was actually reported.
• It's possible that uncertainties in the broader market or concerns about future growth prospects for the company could have also contributed to the bearish sentiment.
• Investors might be waiting for more concrete data from Zoetis' Q3 earnings report to assess the company's performance and make informed decisions about their positions in the stock.

08.06.2025 - ZTS Stock was up 0.7%

• The positive movement in ZTS today may stem from investors acknowledging the company's value in comparison to its peers like SGIOY.
• Positive aspects of ZTS may have been emphasized in a recent comparison, sparking enhanced investor interest and pushing the stock price up.
• The preference for ZTS over SGIOY could be attributed to its solid market standing and growth potential in the animal health sector.